Research & Literature

Sleep-Wake Cycle and Daytime Sleepiness in the Myotonic Dystrophies.

Romigi A, Albanese M, Liguori C, et al.

Journal of neurodegenerative diseases 2013; (2013()):692026 doi:10.1155/2013/692026.

Myotonic disorders: A review article.

Hahn C, Salajegheh MK

Iranian journal of neurology 2016; (15(1)):46-53.

Multidimensional aspects of pain in myotonic dystrophies.

Peric M, Peric S, Rapajic N, et al.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2015; (34(2-3)):126-32.

Two cases of myotonic dystrophy manifesting various ophthalmic findings with genetic evaluation.

Kang MJ, Yim HB, Hwang HB

Indian journal of ophthalmology 2016; (64(7)):535-7 doi:10.4103/0301-4738.190157.

Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism.

Meola G, Cardani R

Journal of neuromuscular diseases 2015; (2(s2)):S59-S71 doi:10.3233/JND-150088.

CRISPR/Cas9-Induced (CTG⋅CAG)n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing.

van Agtmaal EL, André LM, Willemse M, et al.

Molecular therapy : the journal of the American Society of Gene Therapy 2017; (25(1)):24-43 doi:10.1016/j.ymthe.2016.10.014.

Predominantly myalgic phenotype caused by the c.3466G>A p.A1156T mutation in SCN4A gene.

Palmio J, Sandell S, Hanna MG, et al.

Neurology 2017; (88(16)):1520-1527 doi:10.1212/WNL.0000000000003846.

Hard ways towards adulthood: the transition phase in young people with myotonic dystrophy.

Baldanzi S, Ricci G, Simoncini C, et al.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2016; (35(3)):145-149.

Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia.

Finsterer J, Safoschnik G, Witsch-Baumgartner M

SAGE open medical case reports 2017; (5()):2050313X17703021 doi:10.1177/2050313X17703021.

Myotonic Dystrophy Type 1 Clinical, Electrophysiological and Molecular Characterization: Experience at Tertiary Care Centre.

Khadilkar S, Jagiasi K, Yadav J, et al.

The Journal of the Association of Physicians of India 2017; (65(6)):32-37.

High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.

Hilbert JE, Barohn RJ, Clemens PR, et al.

Neurology 2017; (89(13)):1348-1354 doi:10.1212/WNL.0000000000004420.

Myotonic dystrophy type 1 with diabetes mellitus, mixed hypogonadism and adrenal insufficiency.

Takeshima K, Ariyasu H, Ishibashi T, et al.

Endocrinology, diabetes & metabolism case reports 2018; (2018()) doi:10.1530/EDM-17-0143.

Qualitative and Quantitative Aspects of Pain in Patients With Myotonic Dystrophy Type 2.

van Vliet J, Tieleman AA, Verrips A, et al.

The journal of pain 2018; (19(8)):920-930 doi:10.1016/j.jpain.2018.03.006.

Unusual association of a unique CAG interruption in 5' of DM1 CTG repeats with intergenerational contractions and low somatic mosaicism.

Tomé S, Dandelot E, Dogan C, et al.

Human mutation 2018; (39(7)):970-982 doi:10.1002/humu.23531.

Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial.

Bassez G, Audureau E, Hogrel JY, et al.

Brain : a journal of neurology 2018; (141(10)):2855-2865 doi:10.1093/brain/awy231.

Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease.

Wood L, Bassez G, Bleyenheuft C, et al.

Orphanet journal of rare diseases 2018; (13(1)):155 doi:10.1186/s13023-018-0889-0.

Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

LoRusso S, Weiner B, Arnold WD

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2018; (15(4)):872-884 doi:10.1007/s13311-018-00679-z.

Differential Diagnosis between Duchenne Muscular Dystrophy and Limb Girdle Muscular Dystrophy 2a.

Dobrescu MA, Chelu G, Tache DE, et al.

Current health sciences journal 2015; (41(4)):385-389 doi:10.12865/CHSJ.41.04.15.

Quantitative myotonia assessment with a commercially available dynamometer in myotonic dystrophy types 1 and 2.

Horáková M, Horák T, Parmová O, et al.

Muscle & nerve 2019; (59(4)):431-435 doi:10.1002/mus.26401.

Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.

Manta A, Stouth DW, Xhuti D, et al.

The Journal of physiology 2019; (597(5)):1361-1381 doi:10.1113/JP277123.

Prevalence and predictor factors of respiratory impairment in a large cohort of patients with Myotonic Dystrophy type 1 (DM1): A retrospective, cross sectional study.

Rossi S, Della Marca G, Ricci M, et al.

Journal of the neurological sciences 2019; (399()):118-124 doi:10.1016/j.jns.2019.02.012.

What is known about the effects of exercise or training to reduce skeletal muscle impairments of patients with myotonic dystrophy type 1? A scoping review.

Roussel MP, Morin M, Gagnon C, Duchesne E

BMC musculoskeletal disorders 2019; (20(1)):101 doi:10.1186/s12891-019-2458-7.

Sleep-disordered breathing and effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with myotonic dystrophy type I.

Spiesshoefer J, Runte M, Heidbreder A, et al.

Neuromuscular disorders : NMD 2019; (29(4)):302-309 doi:10.1016/j.nmd.2019.02.006.

Myotonic Dystrophy-2: Unusual Phenotype Due to a Small CCTG-expansion.

J F, C S, A RF, et al.

Balkan journal of medical genetics : BJMG 2018; (21(2)):39-43 doi:10.2478/bjmg-2018-0024.

Diabetic Gastroparesis.

Bharucha AE, Kudva YC, Prichard DO

Endocrine reviews 2019; (40(5)):1318-1352 doi:10.1210/er.2018-00161.

Robust Preimplantation Genetic Testing Strategy for Myotonic Dystrophy Type 1 by Bidirectional Triplet-Primed Polymerase Chain Reaction Combined With Multi-microsatellite Haplotyping Following Whole-Genome Amplification.

Lian M, Lee CG, Chong SS

Frontiers in genetics 2019; (10()):589 doi:10.3389/fgene.2019.00589.

Clinical and genetic characteristics of childhood-onset myotonic dystrophy.

Stokes M, Varughese N, Iannaccone S, Castro D

Muscle & nerve 2019; (60(6)):732-738 doi:10.1002/mus.26716.

High incidence of falls in patients with myotonic dystrophy type 1 and 2: A prospective study.

Berends J, Tieleman AA, Horlings CGC, et al.

Neuromuscular disorders : NMD 2019; (29(10)):758-765 doi:10.1016/j.nmd.2019.08.012.

Reproductive Cancer Risk Factors in Women With Myotonic Dystrophy (DM): Survey Data From the US and UK DM Registries.

Higgs C, Hilbert JE, Wood L, et al.

Frontiers in neurology 2019; (10()):1071 doi:10.3389/fneur.2019.01071.

DM1 Phenotype Variability and Triplet Repeat Instability: Challenges in the Development of New Therapies.

Tomé S, Gourdon G

International journal of molecular sciences 2020; (21(2)) doi:10.3390/ijms21020457.

Patient Input to Inform the Development of Central Nervous System Outcome Measures in Myotonic Dystrophy.

White M

Therapeutic innovation & regulatory science 2020; (54(5)):1010-1017 doi:10.1007/s43441-020-00117-3.

Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.

Wu J, Wang C, Toh S, et al.

Pharmacoepidemiology and drug safety 2020; (29(10)):1213-1218 doi:10.1002/pds.4962.

PREPUBERTAL GYNECOMASTIA: A RARE MANIFESTATION OF MYOTONIC DYSTROPHY TYPE 1.

Miranda PSF, Pereira EPMN, Barreto JSCB, et al.

Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo 2020; (38()):e2018294 doi:10.1590/1984-0462/2020/38/2018294.

Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Yadava RS, Yu Q, Mandal M, et al.

Human molecular genetics 2020; (29(9)):1440-1453 doi:10.1093/hmg/ddaa060.

Consensus-Based Care Recommendations for Pulmonologists Treating Adults with Myotonic Dystrophy Type 1.

Boentert M, Cao M, Mass D, et al.

Respiration; international review of thoracic diseases 2020; (99(4)):360-368 doi:10.1159/000505634.

Multisystemic Impairments in 93 Chinese Patients With Myotonic Dystrophy Type 1.

Li M, Wang Z, Cui F, et al.

Frontiers in neurology 2020; (11()):277 doi:10.3389/fneur.2020.00277.

Evaluation of mexiletine effect on conduction delay and bradyarrhythmic complications in patients with myotonic dystrophy type 1 over long-term follow-up.

Vio R, Zorzi A, Bello L, et al.

Heart rhythm 2020; (17(11)):1944-1950 doi:10.1016/j.hrthm.2020.05.043.

[Adult myotonic dystrophy type 1: an update].

Rosado-Bartolomé A, Gutiérrez-Gutiérrez G, Prieto-Matos J

Semergen 2020; (46(5)):355-362 doi:10.1016/j.semerg.2020.01.002.

Predictors of respiratory decline in myotonic dystrophy type 1 (DM1): a longitudinal cohort study.

Mazzoli M, Ariatti A, Garuti G, et al.

Acta neurologica Belgica 2021; (121(1)):133-142 doi:10.1007/s13760-020-01425-z.

A Case of Myotonic Dystrophy Type I With Rimmed Vacuoles in Skeletal Muscle Pathology.

Ban R, Zhang Y, Li K, Shi Q

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2021; (27(8S)):S771-S772 doi:10.1097/RHU.0000000000001496.

Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.

Marsh S, Hanson B, Wood MJA, et al.

Molecular therapy : the journal of the American Society of Gene Therapy 2020; (28(12)):2527-2539 doi:10.1016/j.ymthe.2020.10.005.

Myotonic dystrophy type 2: the 2020 update.

Meola G

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2020; (39(4)):222-234 doi:10.36185/2532-1900-026.

Myotonic Muscular Dystrophy Type 2 in CT, USA: A Single-Center Experience With 50 Patients.

Roy B, Wu Q, Whitaker CH, Felice KJ

Journal of clinical neuromuscular disease 2021; (22(3)):135-146 doi:10.1097/CND.0000000000000340.

High throughput screening for expanded CTG repeats in myotonic dystrophy type 1 using melt curve analysis.

Butterfield RJ, Imburgia C, Mayne K, et al.

Molecular genetics & genomic medicine 2021; (9(4)):e1619 doi:10.1002/mgg3.1619.

Neuropsychological Assessment Should Always be Considered in Myotonic Dystrophy Type 2.

Theodosiou T, Christidi F, Xirou S, et al.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology 2021; (34(1)):1-10 doi:10.1097/WNN.0000000000000263.

Myotonic dystrophy type 1 drug development: A pipeline toward the market.

Pascual-Gilabert M, López-Castel A, Artero R

Drug discovery today 2021; (26(7)):1765-1772 doi:10.1016/j.drudis.2021.03.024.

Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1.

Sansone VA, Proserpio P, Mauro L, et al.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2021; (17(12)):2383-2391 doi:10.5664/jcsm.9438.

Cognitive Deficits, Apathy, and Hypersomnolence Represent the Core Brain Symptoms of Adult-Onset Myotonic Dystrophy Type 1.

Miller JN, Kruger A, Moser DJ, et al.

Frontiers in neurology 2021; (12()):700796 doi:10.3389/fneur.2021.700796.

Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia.

Locci S, Cardani R, Brunori P, et al.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(12)):5365-5368 doi:10.1007/s10072-021-05538-y.

Cardiac Pathology in Myotonic Dystrophy Type 1.

Mahadevan MS, Yadava RS, Mandal M

International journal of molecular sciences 2021; (22(21)) doi:10.3390/ijms222111874.

Myotonic Dystrophies: A Genetic Overview.

Soltanzadeh P

Genes 2022; (13(2)) doi:10.3390/genes13020367.

Overview of the Complex Relationship between Epigenetics Markers, CTG Repeat Instability and Symptoms in Myotonic Dystrophy Type 1.

de Pontual L, Tomé S

International journal of molecular sciences 2022; (23(7)) doi:10.3390/ijms23073477.

Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening.

Jenquin JR, O'Brien AP, Poukalov K, et al.

iScience 2022; (25(5)):104198 doi:10.1016/j.isci.2022.104198.

Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patients.

Ravel-Chapuis A, Duchesne E, Jasmin BJ

The Journal of physiology 2022; (600(14)):3249-3264 doi:10.1113/JP282725.

Cardiac Manifestations of Myotonic Dystrophy in a Pediatric Cohort.

Brunet Garcia L, Hajra A, Field E, et al.

Frontiers in pediatrics 2022; (10()):910660 doi:10.3389/fped.2022.910660.

MECP2-related pathways are dysregulated in a cortical organoid model of myotonic dystrophy.

Morelli KH, Jin W, Shathe S, et al.

Science translational medicine 2022; (14(651)):eabn2375 doi:10.1126/scitranslmed.abn2375.

Milestones of progression in myotonic dystrophy type 1 and type 2.

Hamel JI, McDermott MP, Hilbert JE, et al.

Muscle & nerve 2022; (66(4)):508-512 doi:10.1002/mus.27674.

Arrhythmic CArdiac DEath in MYotonic dystrophy type 1 patients (ACADEMY 1) study: the predictive role of programmed ventricular stimulation.

Russo V, Papa AA, Rago A, et al.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2022; (24(7)):1148-1155 doi:10.1093/europace/euab282.

Executive Dysfunction, Social Cognition Impairment, and Gray Matter Pathology in Myotonic Dystrophy Type 2: A Pilot Study.

Theodosiou T, Christidi F, Xirou S, et al.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology 2022; (35(3)):204-211 doi:10.1097/WNN.0000000000000314.

CRISPRthripsis: The Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy.

Amendola M, Brusson M, Miccio A

Stem cells translational medicine 2022; (11(10)):1003-1009 doi:10.1093/stcltm/szac064.

Complications After Dental Sedation: A Myotonic Mystery Case Report.

Karamlou M, Asaria I, Barron J, et al.

Anesthesia progress 2022; (69(4)):26-31 doi:10.2344/anpr-69-02-09.

Myotonic Dystrophy.

Hamel JI

Continuum (Minneapolis, Minn.) 2022; (28(6)):1715-1734 doi:10.1212/CON.0000000000001184.

A Greek National Cross-Sectional Study on Myotonic Dystrophies.

Papadimas GK, Papadopoulos C, Kekou K, et al.

International journal of molecular sciences 2022; (23(24)) doi:10.3390/ijms232415507.

The myotonic dystrophy type 1 drug development pipeline: 2022 edition.

Pascual-Gilabert M, Artero R, López-Castel A

Drug discovery today 2023; (28(3)):103489 doi:10.1016/j.drudis.2023.103489.

Fluid Biomarkers of Central Nervous System (CNS) Involvement in Myotonic Dystrophy Type 1 (DM1).

Rossi S, Silvestri G

International journal of molecular sciences 2023; (24(3)) doi:10.3390/ijms24032204.

Sporadic Myotonic Dystrophy Type 2 in a Japanese Patient.

Miyashita K, Ii Y, Matsuyama H, et al.

Internal medicine (Tokyo, Japan) 2023; (62(20)):3027-3031 doi:10.2169/internalmedicine.0425-22.

Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model.

Neault N, Ravel-Chapuis A, Baird SD, et al.

International journal of molecular sciences 2023; (24(4)) doi:10.3390/ijms24043794.

Managing thyroid cancer in Steinert's disease: the role of radiofrequency ablation.

Solis-Pazmino P, Carvajal MA, García M, et al.

Journal of surgical case reports 2023; (2023(6)):rjad381 doi:10.1093/jscr/rjad381.

Resistance Exercise Training Rescues Mitochondrial Dysfunction in Skeletal Muscle of Patients with Myotonic Dystrophy Type 1.

Di Leo V, Lawless C, Roussel MP, et al.

Journal of neuromuscular diseases 2023; (10(6)):1111-1126 doi:10.3233/JND-230099.

Impact of gastrointestinal and urological symptoms in children with myotonic dystrophy type 1.

Maagdenberg SJM, Klinkenberg S, Sophie van den Berg J, et al.

Neuromuscular disorders : NMD 2024; (35()):1-7 doi:10.1016/j.nmd.2023.12.011.

Myotonic dystrophy type 1: palliative care guidelines.

Willis D, Willis T, Bassie C, et al.

BMJ supportive & palliative care 2024; doi:10.1136/spcare-2023-004748.

Acetazolamide-responsive myotonia with a novel Ile239Thr mutation in SCN4A gene: a case report.

Yadav J, Barnwal R, Kumar Mandal S, Prajapati B

Annals of medicine and surgery (2012) 2024; (86(2)):1191-1195 doi:10.1097/MS9.0000000000001673.

Natural history of cardiac involvement in myotonic dystrophy type 1 - Emphasis on the need for lifelong follow-up.

Petri H, Mohammad BJY, Kristensen AT, et al.

International journal of cardiology 2024; (406()):132070 doi:10.1016/j.ijcard.2024.132070.

Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy.

Wahbi K, Bassez G, Duchateau J, et al.

Archives of cardiovascular diseases 2024; (117(6-7)):450-456 doi:10.1016/j.acvd.2024.03.001.

Generation of a lymphoblastoid-derived induced pluripotent stem cell line (CBRCULi015-A) from a patient with congenital myotonic dystrophy.

De Serres-Bérard T, Jauvin D, Pouliot V, et al.

Stem cell research 2024; (77()):103430 doi:10.1016/j.scr.2024.103430.

Myotonic dystrophy type 1 testing, 2024 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG).

Seifert BA, Reddi HV, Kang BE, et al.

Genetics in medicine : official journal of the American College of Medical Genetics 2024; (26(8)):101145 doi:10.1016/j.gim.2024.101145.

Excessive daytime sleepiness in myotonic dystrophy: a narrative review.

Hoxhaj D, Pascazio A, Maestri M, et al.

Frontiers in neurology 2024; (15()):1389949 doi:10.3389/fneur.2024.1389949.

Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial.

Vivekanandam V, Skorupinska I, Jayaseelan DL, et al.

The Lancet. Neurology 2024; (23(10)):1004-1012 doi:10.1016/S1474-4422(24)00320-X.

Self-Assembled Antibody-Oligonucleotide Conjugates for Targeted Delivery of Complementary Antisense Oligonucleotides.

Zhou L, Bi J, Chang S, et al.

Angewandte Chemie (International ed. in English) 2025; (64(3)):e202415272 doi:10.1002/anie.202415272.

Maternal health and obstetric complications of genetic neuromuscular disorders in pregnancy: A systematic review.

Ahmed HS, Teli A, Khullar K, Deepak BL

European journal of obstetrics, gynecology, and reproductive biology 2025; (304()):152-170 doi:10.1016/j.ejogrb.2024.11.046.

Investigating phenotypic variability patterns in myotonic dystrophy type 2 in a neuromuscular referral center retrospective cohort.

Picher-Martel V, Locascio JJ, Chuang K, et al.

Neuromuscular disorders : NMD 2025; (47()):105255 doi:10.1016/j.nmd.2024.105255.

FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.

Weeden T, Picariello T, Quinn B, et al.

Communications medicine 2025; (5(1)):22 doi:10.1038/s43856-025-00733-w.

Evaluation of professional practices in the use of mexiletine for the management of childhood myotonia in French pediatric neuromuscular centers (MEXI-PEDI survey).

Barrière S, Manel V, Barnerias C, et al.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2025; (32(2)):107-113 doi:10.1016/j.arcped.2024.10.009.

International collaboration to improve knowledge on myotonic dystrophy type 2.

Peric S, Ivanovic V, Ashley EJ, et al.

Journal of neuromuscular diseases 2024; (11(6)):1229-1237 doi:10.1177/22143602241290353.

Sudden Death Caused by Bilateral Diaphragmatic Eventration in Myotonic Dystrophy Type 1.

Wu S, Prahlow JA

The American journal of forensic medicine and pathology 2025; (46(4)):330-336 doi:10.1097/PAF.0000000000001073.

Adherence to Non-Invasive Ventilation in Steinert Disease: Clinical and Psychological Insights.

Annunziata A, Simioli F, Polistina GE, et al.

Brain sciences 2025; (15(9)) doi:10.3390/brainsci15090968.

Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus.

Luo L, Zhu C, Yang S, et al.

Frontiers in neurology 2025; (16()):1640563 doi:10.3389/fneur.2025.1640563.

Balanced Translocations Involving the DMD Gene as a Cause of Muscular Dystrophy in Female Children: A Description of Three Cases.

Vorontsova EO, Murtazina A, Zinina E, et al.

International journal of molecular sciences 2025; (26(19)) doi:10.3390/ijms26199389.

Physiology of Abnormal Muscle Fiber Generators.

Dumitru D, Nandedkar SD, Barkhaus PE

Muscle & nerve 2026; (73(1)):7-27 doi:10.1002/mus.70035.

Health-related quality of life, pain, and fatigue in myotonic dystrophy type 2: a 13-year follow-up study.

Damen MJ, Mul K, van Engelen BGM, et al.

Disability and rehabilitation 2025; 1-8 doi:10.1080/09638288.2025.2571068.

Potential pitfalls in the differential diagnosis of myositis versus hereditary myopathies.

Glaubitz S, Zeng R, Hasanov K, et al.

Clinical and experimental rheumatology 2026; (44(2)):304-312 doi:10.55563/clinexprheumatol/pqmby3.

An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

Johnson NE, Tai LJ, Hamel JI, et al.

The New England journal of medicine 2026; (394(8)):763-772 doi:10.1056/NEJMoa2407326.